Behold.ai
Behold.ai provides the red dot® AI platform for autonomous radiology diagnosis across chest X-ray (lung cancer detection) and CT head (stroke triage), serving NHS Trusts in the UK, Apollo Hospitals in India, and US systems via Merative.
- Company typePrivate
- Founded2017
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
Behold.ai firmographics
Firmographics- Name
- Behold.ai
- Legal name
- Behold.ai Global Technologies Limited
- Website
- https://behold.ai
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Behold.ai provides the red dot® AI platform for autonomous radiology diagnosis across chest X-ray (lung cancer detection) and CT head (stroke triage), serving NHS Trusts in the UK, Apollo Hospitals in India, and US systems via Merative.
- Ownership category
- akta.pro rank
Behold.ai industry classification
Industry- Product category
- AI Radiology Diagnostics Software
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)
Keywords
Where Behold.ai is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Behold.ai business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Per Exam Pricing: The company charges on a per exam basis for the red dot® algorithm triage and instant triage services, particularly for the FDA-cleared pneumothorax detection functionality.
- NHS Framework / Contract Revenue: Approved for NHS Share Business Framework with Phase 4 AI Award winner for national rollout. Revenue generated through NHS trust contracts for the lung cancer detection platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Per exam pricing model for AI triage services |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Behold.ai product offering
Product offeringCore offering
Behold.ai develops and sells the red dot® AI-powered diagnostic platform — a Software as a Medical Device that processes chest X-rays and CT head scans to automatically identify normal examinations and triage suspected critical findings (lung cancer, intracranial haemorrhage, acute infarct, pneumothorax). The platform is sold to NHS Trusts in the UK via direct sales and NHS framework contracts, and internationally through channel partners Merative (US) and Apollo Hospitals (India).
Product overview
Behold.ai offers the red dot® AI-powered diagnostic platform for CT and X-ray imaging. The platform comprises two core products: the red dot® Lung Cancer Detection Platform for chest X-ray analysis and the red dot® CTH V1 for CT head examinations. Both products leverage the same proprietary AI algorithm to provide rapid, autonomous diagnosis that identifies normal examinations for auto-reporting and flags urgent findings for prioritization. The platform integrates seamlessly with existing hospital RIS and PACS systems and has demonstrated robust clinical validation with zero missed lung cancers over three years using the Rule-Out AI functionality.
Differentiator
Problem solved
Functional benefit
Brands
- red dot®: Award-winning AI-powered diagnostic platform for CT and X-ray imaging designed for rapid and accurate detection of critical conditions such as lung cancer and stroke. The platform includes red dot® Lung Cancer Detection Platform (for chest X-rays) and red dot® CTH V1 (for CT head examinations).
Products and services
- red dot® Lung Cancer Detection Platform FDA-cleared and CE-marked AI platform that automatically identifies normal adult (18+) frontal chest X-rays and triages potential lung cancer cases for faster clinical decision-making, returning results within 30 seconds with heatmap visualization.
- red dot® CTH V1 AI-powered CT Head algorithm enabling 24/7 triage of acute findings and rule-out of normal CT head examinations. Identifies intracranial haemorrhage (ICH) and acute infarct within 5 minutes, prioritizing patients for urgent care.
- red dot® V2 Clinical Analysis Software Updated version of the red dot® AI platform that autonomously rules out normal patients presenting for chest X-ray in 7 seconds and identifies priority suspected lung cancer cases in combination with radiologists.
Quantifiable outcome
- 71% reduction in average time from CXR to CXR report (from 7 days to 2 days)
- +6 more outcomes
Companies that use Behold.ai
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Behold.ai technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability5 records
Feature5 records
Behold.ai partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- Wellbeing SoftwarecoreCollaboration on national solution for rapid COVID-19 diagnosis using AI analysis of chest X-rays. Wellbeing Software operates Cris, the UK's most widely used Radiology Information System (RIS), installed in over 700 locations. Integration enables fast-track national rollout across NHS hospitals.
- Apollo Hospitals Group / Apollo Radiology InternationalcorePartnership for rapid COVID-19 diagnosis using AI-based chest X-ray technology. World's largest deployment of radiology-based AI diagnostic solution for COVID-19. Deployed in Apollo's network of 71 hospitals in India with 12,000 beds. Analyzed 82,093 CXR exams over 19 months.
- MerativecoreUS distribution partnership where Merative distributes red dot® AI radiology solutions. Merative has over 23% of PACS imaging systems market share in the US, providing significant market access for Behold.ai's FDA-cleared pneumothorax triage product.
- Amazon Web Services (AWS) Diagnostic Development InitiativesupportingAWS initiative supporting the Apollo Hospitals partnership for COVID-19 diagnostic development. The initiative accelerates research and innovation on COVID-19 and infectious diseases through early disease detection, diagnostics, prognosis and public health genomics.
- NHSX / Accelerated Access CollaborativecoreGovernment funding through the AI in Health and Care Award Phase 4. Award provides funding for set-up of clinical trials sites in NHS radiology departments and supports initial national adoption. One of 38 organisations to receive funding under the NHS Long Term Plan AI initiatives.
- NHS Share Business Services AuthoritycoreBehold.ai is an approved supplier on the NHS Share Business Framework, enabling direct procurement by NHS Trusts across England for the red dot® lung cancer detection platform.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Behold.ai competitors and assessment
Company assessmentDirect peers
- Qure.ai: Direct competitor in AI-powered radiology for chest X-ray and CT head, with FDA-cleared products for head CT, chest CT, and chest X-ray. Most directly comparable peer given similar product focus and target customers (hospitals globally).
- RapidAI: AI imaging company specializing in stroke and CT/MRI brain analysis with care coordination workflow. Comparable peer for CT head triage and neurology-focused clinical pathways.
- Viz.ai: AI platform focused on CT head for stroke detection (large vessel occlusion) and care coordination. Directly comparable for the red dot CTH V1 stroke/triage use case, with similar FDA clearance pathway and hospital sales motion.
- Annalise.ai: Radiology AI platform covering chest X-ray and CT head with autonomous reporting capabilities, FDA and CE cleared. Closely comparable in regulatory positioning and product scope.
- Lunit: Korean AI company developing radiology AI for chest X-ray (Lunit INSIGHT CXR) with FDA clearance and CE mark. Direct peer with similar focus on lung nodule/cancer detection and global hospital customer base.
- Aidoc: Broad radiology AI platform with FDA-cleared algorithms for CT head (haemorrhage, stroke) and other acute findings. Direct peer in CT head triage and broader hospital radiology AI market.
- Nanox (formerly Zebra Medical Vision): Broad radiology AI platform with multiple FDA-cleared algorithms covering chest, bone, and other findings. Comparable peer in AI radiology commercialization model and hospital sales approach.
Broad incumbents
- Announcement: iCAD (ProFound AI): Medical imaging AI vendor focused on mammography and CT with FDA-cleared products. Comparable incumbent in radiology AI commercialization with regulatory depth and clinical evidence.
- Merative (formerly IBM Watson Health Imaging): Owns 23%+ US PACS imaging market share and distributes Behold.ai's pneumothorax product. Established PACS vendor and channel partner that could also compete with embedded AI capabilities.
- Siemens Healthineers AI-Rad Companion: Major imaging equipment vendor with embedded AI-Rad Companion platform for chest CT and other modalities. Broad incumbent that competes by integrating AI directly with installed imaging equipment base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Behold.ai social profiles
Digital presenceBehold.ai compliance and trust
Trust signalCompliance5 records
Behold.ai financial estimates
Financial estimateRevenue estimate
Valuation estimate
Behold.ai leadership team
Management profileNumber of profiles
Profiles3 records
Behold.ai funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Behold.ai M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Behold.ai
What does Behold.ai do?
Behold.ai develops and sells the red dot® AI-powered diagnostic platform — a Software as a Medical Device that processes chest X-rays and CT head scans to automatically identify normal examinations and triage suspected critical findings (lung cancer, intracranial haemorrhage, acute infarct, pneumothorax). The platform is sold to NHS Trusts in the UK via direct sales and NHS framework contracts, and internationally through channel partners Merative (US) and Apollo Hospitals (India).
Is Behold.ai a public or private company?
Behold.ai is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Behold.ai founded?
Behold.ai was founded in 2017. It employs 51 to 100 people.
Where is Behold.ai based?
Behold.ai is headquartered in London, United Kingdom, in the Europe region.
How does Behold.ai make money?
Two revenue lines are on record. Per Exam Pricing is the primary driver. The others are NHS Framework / Contract Revenue.
Who are Behold.ai's main competitors?
Direct peers on record are Qure.ai, RapidAI, Viz.ai, Annalise.ai, Lunit, Aidoc and Nanox (formerly Zebra Medical Vision). Broad incumbents are Announcement: iCAD (ProFound AI), Merative (formerly IBM Watson Health Imaging) and Siemens Healthineers AI-Rad Companion.
Does Behold.ai have an API?
No public API is recorded for Behold.ai.
What industry is Behold.ai in?
Behold.ai's product category is AI Radiology Diagnostics Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 3391 and its SIC code is 3841.